ArticleJournal for immunotherapy of cancer2021

Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors.

Thomas Kelleher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.